↓ Skip to main content

Identification of clear cell renal cell carcinoma and oncocytoma using a three-gene promoter methylation panel

Overview of attention for article published in Journal of Translational Medicine, June 2017
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
20 Dimensions

Readers on

mendeley
29 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Identification of clear cell renal cell carcinoma and oncocytoma using a three-gene promoter methylation panel
Published in
Journal of Translational Medicine, June 2017
DOI 10.1186/s12967-017-1248-y
Pubmed ID
Authors

Ana Sílvia Pires-Luís, Pedro Costa-Pinheiro, Maria João Ferreira, Luís Antunes, Francisco Lobo, Jorge Oliveira, Rui Henrique, Carmen Jerónimo

Abstract

Promoter methylation has emerged as a promising class of epigenetic biomarkers for diagnosis and prognosis of renal cell tumors (RCTs). Although differential gene promoter methylation patterns have been reported for the major subtypes (clear cell, papillary and chromophobe renal cell carcinoma, and oncocytoma), validation of diagnostic performance in independent series have been seldom performed. Herein, we aimed at assessing the diagnostic performance of genes previously shown to be hypermethylated in RCTs in different clinical settings. Promoter methylation levels of HOXA9 and OXR1 were assessed by quantitative methylation specific PCR. ROC curves were generated for OXR1, OXR1 combined with MST1R and HOXA9. Sensitivity, specificity, positive predictive value, negative predictive value and accuracy were computed, maximizing specificity. Methylation levels were also correlated with clinical and pathological relevant parameters. HOXA9 and OXR1 promoter methylation was disclosed in 73 and 87% of RCTs, respectively. A two-gene methylation panel comprising OXR1 and MST1R identified malignancy with 98% sensitivity and 100% specificity, and clear cell renal cell carcinoma with 90% sensitivity and 98% specificity. HOXA9 promoter methylation allowed for discrimination between oncocytoma and both papillary and chromophobe renal cell carcinoma but only with 77% sensitivity and 73% specificity. Significantly higher OXR1 promoter methylation levels (p = 0.005) were associated with high nuclear grade in ccRCC. A panel including OXR1 and MST1R promoter methylation allows specific and sensitive identification of renal cell tumors, and, especially, of clear cell renal cell carcinoma. Moreover, higher OXR1 promoter methylation levels associate with clear cell renal cell carcinoma nuclear grade, a surrogate for tumor aggressiveness. Thus, gene promoter methylation analysis might a useful ancillary tool in diagnostic management of renal masses.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 29 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 21%
Student > Ph. D. Student 4 14%
Student > Doctoral Student 2 7%
Student > Bachelor 2 7%
Other 2 7%
Other 6 21%
Unknown 7 24%
Readers by discipline Count As %
Medicine and Dentistry 9 31%
Biochemistry, Genetics and Molecular Biology 4 14%
Agricultural and Biological Sciences 3 10%
Nursing and Health Professions 1 3%
Mathematics 1 3%
Other 1 3%
Unknown 10 34%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 June 2017.
All research outputs
#15,467,628
of 22,985,065 outputs
Outputs from Journal of Translational Medicine
#2,254
of 4,017 outputs
Outputs of similar age
#198,591
of 315,315 outputs
Outputs of similar age from Journal of Translational Medicine
#40
of 68 outputs
Altmetric has tracked 22,985,065 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,017 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one is in the 31st percentile – i.e., 31% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 315,315 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 68 others from the same source and published within six weeks on either side of this one. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.